Hanna-Maija Kuusisto

Keyphrases

1. Alemtuzumab 22%
2. Central Hospitals 18%
3. Chronic Disease 18%
4. Cladribine Tablets 18%
5. Clinical Outcomes 18%
6. Confidence Interval 18%
7. COVID-19 Pandemic 37%
8. Digital Services 56%
9. Disease-modifying Therapy 66%
10. Do-not-resuscitate Orders 37%
11. E-health 18%
12. Elderly People 18%
13. Finland 100%
14. Health Decision-making 44%
15. Health Technology 18%
16. Healthcare 40%
17. Healthcare Decisions 22%
18. Healthcare Professionals 60%
19. Healthcare Workers' Perceptions 37%
20. Human Resources 18%
21. Information Provision 18%
22. Information Quality 18%
23. Initial Treatment Strategy 18%
24. John Cunningham Virus 18%
25. Medication Adherence 18%
26. MS Patients 18%
27. Multiple Sclerosis 73%
28. Multiple Sclerosis Treatment 71%
29. Natalizumab 22%
30. National Cohort Study 18%
31. Nationwide Registry 18%
32. Neurologist 37%
33. Non-adherence 18%
34. Non-reporting 18%
35. Older Adults 41%
36. Patient Safety Incident 26%
37. Patient-reported Data 30%
38. Professional Opinion 18%
39. Professionals' Reactions 18%
40. Propensity Score Matching Study 18%
41. Real-world Clinical Outcomes 18%
42. Scoping Review Protocol 18%
43. Shared Decision Making 61%
44. Social Care 26%
45. Subjective Rationality 18%
46. Teleneurology 18%
47. Teriflunomide 22%
48. Treatment Safety 18%
49. Tumefactive multiple Sclerosis 22%
50. Vaccination 18%